Abstract: Chimeric antigen receptor T (CAR⁃T) cell therapy, as a novel tumor immunotherapy, has achieved remarkable results in the treatment of relapsed/refractory hematological malignancies. However, the occurrence of CAR⁃T cell therapy⁃related adverse reactions has impacted its clinical benefits. This article reviews the classification and characteristics, risk factors, monitoring and assessment, preventive measures, and recent advancements in management of CAR⁃T cell therapy⁃related adverse reactions. It also summarizes the current status and challenges the management of CAR⁃T cell therapy⁃related adverse reactions and looks forward to future research directions, aiming to provide clinicians with the latest research progress and practical guidance in this field to promote the safe and effective application of CAR⁃T cell therapy.

Key words: CAR-T cell therapy, Adverse reactions, Cytokine release syndrome, Neurotoxicity, Multidisciplinary management